A randomized double-blind, double dummy, placebo and lorazepam-controlled, 4-way cross-over study to evaluate the pharmacodynamics of single oral doses of BNC210 in healthy young male subjects.

Trial Profile

A randomized double-blind, double dummy, placebo and lorazepam-controlled, 4-way cross-over study to evaluate the pharmacodynamics of single oral doses of BNC210 in healthy young male subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Sep 2011

At a glance

  • Drugs BNC 210 (Primary) ; Lorazepam
  • Indications Anxiety disorders; Panic symptoms
  • Focus Pharmacodynamics
  • Most Recent Events

    • 01 Sep 2011 Results reported in a Bionomics media release, and to be presented at the European College of Neuropsychopharmacology (ECNP).
    • 30 Mar 2011 Positive results have been reported in a Bionomics media release; the company anticipates that data from this trial will be presented at a major scientific conference later this year.
    • 30 Mar 2011 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top